Trials / Completed
CompletedNCT05586919
Treatment of Venous Malformation
Treatment of Venous Malformation by Direct Puncture Repair: Ethanol Versus Polidocanol
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Al-Azhar University · Academic / Other
- Sex
- All
- Age
- 18 Months – 36 Years
- Healthy volunteers
- Not accepted
Summary
Vascular malformations are birth defects that happen when different stages of angiogenesis shut down. 44 - 64% of all vascular malformations are venous malformations (VMs). Sclerotherapy is the first treatment line for VMs. It acts by getting rid of the vascular endothelial cells in the lesion. One of the most common and well researched sclerosing agents for VMs is polidocanol, which is a popular counterpart for concentrated ethanol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Direct Puncture Repair / Ethanol | Ethanol is an organic compound that will be injected in the venous malformation as a sclerotherapy by Direct Puncture Repair |
| PROCEDURE | Direct Puncture Repair / Polidocanol | Polidocanol is a sclerosing agent that will be injected in the venous malformation by Direct Puncture Repair |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2021-01-01
- Completion
- 2021-03-01
- First posted
- 2022-10-19
- Last updated
- 2022-10-19
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05586919. Inclusion in this directory is not an endorsement.